Lauren Rusckowski Duprey Sells 47,586 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Lauren Rusckowski Duprey sold 47,586 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $813,720.60. Following the sale, the insider directly owned 226,057 shares in the company, valued at $3,865,574.70. The trade was a 17.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Price Performance

TAK stock opened at $17.41 on Friday. The company has a fifty day moving average price of $16.53 and a 200-day moving average price of $17.14. The company has a market capitalization of $55.77 billion, a P/E ratio of 51.19 and a beta of -0.08. Takeda Pharmaceutical Co. has a 52-week low of $12.99 and a 52-week high of $18.90. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. The company had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. As a group, equities analysts expect that Takeda Pharmaceutical Co. will post 3.01 EPS for the current year.

Key Takeda Pharmaceutical News

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: The tax-related nature of the transactions reduces their significance as a signal of deteriorating management confidence. Insiders continued to retain substantial positions after selling, including CEO Julie So-Young Kim, who retained 391,489 shares, and Andrew Stewart Plump, who retained 766,569 shares. Takeda insider sales report
• Neutral Sentiment: Analyst views remain mixed, with two Buy ratings, one Hold and one Sell, producing a consensus rating of “Hold.” Institutional ownership is relatively limited at 9.17%, although several funds recently increased their positions. Takeda stock analysis
• Neutral Sentiment: Takeda’s latest reported quarter included $0.56 in EPS and $6.90 billion in revenue. Analysts expect approximately $3.01 in earnings per share for the current year, providing a fundamental backdrop for the stock as it trades near its 12-month high. Takeda financial data
• Negative Sentiment: Multiple insiders sold a combined 444,100 shares for approximately $7.59 million at an average price of $17.10. The sellers included CEO Julie So-Young Kim, General Counsel Natalie Anne Marie Furney, Andrew Stewart Plump and other executives; individual ownership reductions ranged from 5.9% to 18.5%. The volume and seniority of the sellers may weigh on sentiment, even though the sales were made for tax purposes. SEC insider filing

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TAK. Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC boosted its holdings in shares of Takeda Pharmaceutical by 14.2% during the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after buying an additional 370,800 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Takeda Pharmaceutical during the 4th quarter valued at $998,000. Quantinno Capital Management LP lifted its position in shares of Takeda Pharmaceutical by 20.6% during the 1st quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock valued at $23,878,000 after acquiring an additional 219,999 shares during the period. Bleakley Financial Group LLC boosted its stake in Takeda Pharmaceutical by 19.0% during the first quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company’s stock worth $7,993,000 after acquiring an additional 68,844 shares in the last quarter. Finally, Sivia Capital Partners LLC bought a new position in Takeda Pharmaceutical during the second quarter worth $351,000. 9.17% of the stock is owned by institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.